SCHEMBL1630195

SCHEMBL1630195

NNC(=O)CCCCC(=O)NN.[H+]

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.60
KDM4E B2RXH2 2/20 0.57
CTSD P07339 1/20 0.57
KDM5C P41229 1/20 0.57
PHF8 Q9UPP1 1/20 0.57
KDM2A Q9Y2K7 1/20 0.57
GAA P10253 1/20 0.56
HDAC3 O15379 1/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC2 Q92769 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
HDAC5 Q9UQL6 1/20 0.48
MAPT P10636 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.41
LMNA P02545 1/20 0.40
CYP1A2 P05177 2/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28375714 0.97 ALDH1A1 (0.64) ALDH1A1KDM4ECTSDKDM5CPHF8
SCHEMBL49856 0.97 ALDH1A1 (0.62) ALDH1A1KDM4ECTSDKDM5CPHF8
SCHEMBL28219205 0.97 ALDH1A1 (0.62) ALDH1A1KDM4ECTSDKDM5CPHF8
Ammonia Solution, Strong SCHEMBL15129241 0.94 ALDH1A1 (0.60) ALDH1A1KDM4ECTSDKDM5CPHF8
SCHEMBL219713 0.94 ALDH1A1 (0.67) ALDH1A1KDM4ECTSDKDM5CPHF8
SCHEMBL466559 0.94 ALDH1A1 (0.67) ALDH1A1KDM4ECTSDKDM5CPHF8
SCHEMBL4187314 0.94 KDM4E (0.65) ALDH1A1KDM4ECTSDKDM5CPHF8
SCHEMBL4186692 0.94 ALDH1A1 (0.67) ALDH1A1KDM4ECTSDKDM5CPHF8
SCHEMBL10396767 0.94 ALDH1A1 (0.67) ALDH1A1KDM4ECTSDKDM5CPHF8
SCHEMBL9007204 0.94 ALDH1A1 (0.60) ALDH1A1KDM4ECTSDKDM5CPHF8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859523-B2 Crosslinked compounds and methods of making and using thereof UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2014-10-14 US disclosed
EP-1539799-B1 CROSSLINKED COMPOUNDS AND METHODS OF MAKING AND USING THEREOF UNIV UTAH RES FOUND (US) 2013-12-11 EP disclosed
US-7928069-B2 Crosslinked compounds and methods of making and using thereof UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2011-04-19 US disclosed
US-20090117078-A1 CROSSLINKED COMPOUNDS AND METHODS OF MAKING AND USING THEREOF UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2009-05-07 US disclosed
US-20090105193-A1 CROSSLINKED COMPOUNDS AND METHODS OF MAKING AND USING THEREOF UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2009-04-23 US disclosed
EP-1539799-A4 CROSSLINKED COMPOUNDS AND METHODS OF MAKING AND USING THEREOF UNIV UTAH RES FOUND (US) 2008-07-30 EP disclosed
US-20050176620-A1 crosslinked compounds useful in numerous treatments. Described herein are methods of making crosslinked compounds via (1) the oxidative coupling of two or more thiol compounds or (2) by the reaction between at least one tbiol compound with at least one thiol-reactive compound. NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2005-08-11 US disclosed
EP-1539799-A2 CROSSLINKED COMPOUNDS AND METHODS OF MAKING AND USING THEREOF The University of Utah Research Foundation (US) 2005-06-15 EP disclosed
WO-2004037164-A2 CROSSLINKED COMPOUNDS AND METHODS OF MAKING AND USING THEREOF UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2004-05-06 WO disclosed
EP-1305355-A1 HYDROGEL FILMS AND METHODS OF MAKING AND USING THEREFOR The University of Utah Research Foundation (US) 2003-05-02 EP disclosed
WO-2002006373-A1 HYDROGEL FILMS AND METHODS OF MAKING AND USING THEREFOR UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090117078-A1 CROSSLINKED COMPOUNDS AND METHODS OF MAKING AND USING THEREOF APEX1, GPX4, LIG4 ALDH1A1 399/4885KDM4E 1727/4885CTSD 1873/4885
US-20090105193-A1 CROSSLINKED COMPOUNDS AND METHODS OF MAKING AND USING THEREOF APEX1, GPX4, MGMT ALDH1A1 469/4885KDM4E 1791/4885CTSD 2030/4885
US-20050176620-A1 crosslinked compounds useful in numerous treatments. Described herein are methods of making crosslinked compounds via (1) the oxidative coupling of two or more thiol compounds or (2) by the reaction between at least one tbiol compound with at least one thiol-reactive compound. TXN2, APEX1, MGMT ALDH1A1 1151/4885KDM4E 3930/4885CTSD 1287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.